TAM
INSM icon

Tiverton Asset Management’s Insmed INSM Stock Holding History

Tiverton Asset Management’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-23,416
Closed -$600K – 724
2019
Q2 		$600K Buy
23,416
+18,433
+370% +$513K 0.02% 347
2019
Q1 		$145K Buy
+4,983
New +$129K 0.01% 549

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Tiverton Asset Management's INSM Position: Q3 2019 in Review

Tiverton Asset Management sold out of Insmed (INSM) in Q3 2019, closing a stake of 23,416 shares — an estimated $600K sold.

Tiverton Asset Management first reported a position in INSM in Q1 2019 and held it in 2 quarters. The position peaked at $600K in Q2 2019. 157 funds tracked by Wall St. Rank hold INSM as of Q3 2019.

  • Tiverton Asset Management reported no remaining Insmed position as of Q3 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 23,416 Insmed shares in Q3 2019, an estimated $600K.
  • Tiverton Asset Management first reported a position in Insmed in Q1 2019 and held it in 2 quarters.
  • Tiverton Asset Management's Insmed position peaked at $600K in Q2 2019.
  • 157 funds tracked by Wall St. Rank held Insmed as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.